World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
144
Citations
111582
World Ranking
1408
National Ranking
822

Stephen B. Hanauer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stephen B. Hanauer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 988 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stephen B. Hanauer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stephen B. Hanauer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 144 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stephen B. Hanauer is affiliated with Northwestern University in the United States. Their research spans multiple fields within medicine and biological sciences, with a particular focus on gastrointestinal disorders and immune-related diseases.

The scientist's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, key subfields of their work are Genetics, Epidemiology, Immunology, Surgery, and Oncology.

The primary topics covered in their research consist of:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Biosimilars and Bioanalytical Methods
  • Immunodeficiency and Autoimmune Disorders
  • Eosinophilic Esophagitis
  • Cancer Immunotherapy and Biomarkers
  • Liver Diseases and Immunity

Stephen B. Hanauer has contributed to a significant number of publications in leading journals within their field. The most frequent publication venues are:

  • Gastroenterology (48 publications)
  • Journal of Crohn's and Colitis (30 publications)
  • The American Journal of Gastroenterology (26 publications)
  • Inflammatory Bowel Diseases (21 publications)
  • Clinical Gastroenterology and Hepatology (6 publications)

The scientist has collaborated extensively with several researchers, including:

  • Silvio Danese (55 co-authored works)
  • William J. Sandborn (44 co-authored works)
  • Bruce E. Sands (32 co-authored works)
  • Jean-Frédéric Colombel (31 co-authored works)
  • Stefan Schreiber (29 co-authored works)

Some of their recent papers reflect ongoing interests in therapeutic interventions and clinical management of inflammatory bowel diseases and related conditions. These papers include:

  • Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis, 2021, New England Journal of Medicine
  • Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial, 2022, The Lancet
  • Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial, 2021, Clinical Gastroenterology and Hepatology
  • Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting, 2020, Gastroenterology
  • Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study, 2021, Journal for ImmunoTherapy of Cancer

Best Publications

  • A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

    Yasunori Ogura;Denise K. Bonen;Naohiro Inohara;Dan L. Nicolae

  • Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

    Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer

  • A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

    S. R. Targan;S. B. Hanauer;S. J. H. Van Deventer;L. Mayer

  • Infliximab for induction and maintenance therapy for ulcerative colitis.

    Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch

  • Infliximab for the treatment of fistulas in patients with Crohn's disease.

    D.H. Present;P.J. Rutgeerts;S.R. Targan;S.B. Hanauer

  • Vedolizumab as induction and maintenance therapy for ulcerative colitis.

    Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer

  • Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

    Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns

  • Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

    William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer

  • Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy

    Simon Lichtiger;Daniel H. Present;Asher Kornbluth;Irwin Gelernt

  • Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak

  • Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

    L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch

  • A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

    Geert D’Haens;William J. Sandborn;Brian G. Feagan;Karel Geboes

  • A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

    Christoph Gasche;Jurgen Scholmerich;Jorn Brynskov;Geert D'Haens

  • Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.

    Stephen B Hanauer

  • Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

    Paul Rutgeerts;G D'Haens;S Targan;E Vasiliauskas

  • Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

    William J. Sandborn;Stephen B. Hanauer;Seymour Katz;Michael Safdi

  • Maintenance Therapy with Certolizumab Pegol for Crohn's Disease

    Stefan Schreiber;Mani Khaliq-Kareemi;Ian C. Lawrance;Ole Østergaard Thomsen

  • Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

    William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak

  • Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

    William J. Sandborn;Paul Rutgeerts;Robert Enns;Stephen B. Hanauer

  • Management of Crohn's Disease in Adults

    Gary R Lichtenstein;Stephen B Hanauer;Stephen B Hanauer;Stephen B Hanauer;William J Sandborn;William J Sandborn;William J Sandborn

Frequent Co-Authors

William J. Sandborn
William J. Sandborn University of California, San Diego
Brian G. Feagan
Brian G. Feagan University of Western Ontario
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai
David T. Rubin
David T. Rubin University of Chicago
Bruce E. Sands
Bruce E. Sands Icahn School of Medicine at Mount Sinai
Subrata Ghosh
Subrata Ghosh University College Cork
Gary R. Lichtenstein
Gary R. Lichtenstein University of Pennsylvania
Stefan Schreiber
Stefan Schreiber Kiel University
Walter Reinisch
Walter Reinisch Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always follow a traditional path. Many students and professionals consider related online degrees to diversify or specialize their expertise. For those interested in mental health, online msn pmhnp programs offer a flexible way to become a Psychiatric Mental Health Nurse Practitioner, meeting the high demand for mental health providers.

Healthcare administration is another rapidly growing field. Earning healthcare administration degrees online can lead to management or leadership roles in hospitals, clinics, or insurance companies. Cost is a major factor for many students, making it important to compare the masters in healthcare administration cost before enrolling.

For nurses seeking to reach the highest level of clinical practice, the best online bsn to dnp programs allow working professionals to study remotely and advance their qualifications. These career pathways offer flexibility, affordability, and a wide range of options for those passionate about healthcare, both in clinical and non-clinical roles.

Best Scientists Citing Stephen B. Hanauer

Trending Scientists

Recently Published Articles